Pre-antiretroviral therapy plasma levels of CCL2 may aid in the prediction of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV patients after they commence antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 2, 2013, Pages

  Oliver, Benjamin G ^a   Haddow, Lewis J ^b,c   Agarwal, Upasna ^d   Kumar, Manoj ^e   Easterbrook, Philippa J ^c   Moosa, Mahomed Yunus ^b   Singh, Sarman ^b   Price, Patricia ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d LRS Institute of TB and Respiratory Diseases   (India)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD14 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 18; INTERLEUKIN 8; LIPOARABINOMANNAN; MACROPHAGE DERIVED CHEMOKINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CCL2 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LETTER; LEUKOCYTE ACTIVATION; LIMIT OF DETECTION; LUNG TUBERCULOSIS; MACROPHAGE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SOUTH AFRICA; TREATMENT DURATION; TUBERCULOSIS ASSOCIATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; BLOOD; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; PROGNOSIS; TUBERCULOSIS;

ANTI-HIV AGENTS; ANTIGENS, CD14; CHEMOKINE CCL2; CHEMOKINE CXCL10; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTERLEUKIN-18; INTERLEUKIN-8; MACROPHAGE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL ACTIVATION; PROGNOSIS; TUBERCULOSIS;

EID: 84879776948     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828e6182     Document Type: Letter

References (24)

1. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365: 1492-1501.
2. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481.
3. Haddow LJ, Moosa MY, Mosam A, et al. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitu-tion inflammatory syndrome in South Africa. PLoS ONE. 2012;7:e40623.
4. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-523.
5. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis. 2009;48:829-831.
6. Kumar M, Agrawal U, Kumar A, et al. Tubercular immune restoration disease in Indian AIDS patients receiving antiretroviral therapy. Presented at: Australasian HIV/AIDS Conference; September 9-11, 2009; Brisbane, Australia.
7. Price P, Murdoch DM, Agarwal U, et al. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Micro-biol Rev. 2009;22:651-663.
8. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antire-troviral treatment service in South Africa. AIDS. 2007;21:335-341.
9. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med. 2012;157:313-324.
10. Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and anti-tubercular drug resistance. Clin Infect Dis. 2009; 48:667-676.
11. Conesa-Botella A, Loembe MM, Manabe YC, et al. Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome. J Acquir Immune Defic Syndr. 2011;58:463-468.
12. Oliver BG, Elliott JH, Price P, et al. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. J Infect Dis. 2010;202:1728-1737.
13. Hasan Z, Cliff JM, Dockrell HM, et al. CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis. PLoS ONE. 2009;4:e8459.
14. Zhang Y, Broser M, Cohen H, et al. Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacte-rium tuberculosis and its components. J Clin Invest. 1995;95:586-592.
15. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis. 2010; 202:962-970.
16. Haddow LJ, Dibben O, Moosa MY, et al. Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2011;25:1163-1174.
17. Meintjes G, Skolimowska KH, Wilkinson KA, et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitu-tion inflammatory syndrome. Am J Respir Crit Care Med. 2012;186:369-377.
18. Tadokera R, Meintjes G, Skolimowska KH, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J. 2011;37:1248-1259.
19. Sumatoh HR, Oliver BG, Kumar M, et al. Mycobacterial antibody levels and immune restoration disease in HIV patients treated in South East Asia. Biomark Med. 2011;5:847-853.
20. Price P, Haddow LJ, Affandi J, et al. Plasma levels of vitamin D in HIV patients initiating antiretroviral therapy do not predict immune restoration disease associated with Mycobac-terium tuberculosis. AIDS Res Hum Retrovi-ruses. 2012;28:1216-1219.
21. Haddow LJ, Moosa MY, Easterbrook PJ. Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24: 103-108.
22. Schreiber O, Steinwede K, Ding N, et al. Mice that overexpress CC chemokine ligand 2 in their lungs show increased protective immunity to infection with Mycobacterium bovis bacille Calm-ette-Guerin. J Infect Dis. 2008;198:1044-1054.
23. Hasan Z, Jamil B, Ashraf M, et al. Differential live Mycobacterium tuberculosis-, M. bovis BCG-, recombinant ESAT6-, and culture filtrate protein 10-induced immunity in tuberculosis. Clin Vaccine Immunol. 2009;16:991-998.
24. Hasan Z, Jamil B, Khan J, et al. Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in pulmonary and ex-trapulmonary tuberculosis is dependent on disease severity. Scand J Immunol. 2009;69:259-267.